Activiomics
London
About Activiomics
Activiomics Ltd. has developed a groundbreaking and patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled. Activiomics' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of phosphorylation sites. Phosphorylation is critical mediator all cellular processes and hence sites of phosphorylation represent an important class of novel biomarkers. Activiomics' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $805.0K
- Funding stage: M&A
- Last round: Series Unknown (Mar 2011)
- Website: activiomics.com
- Phone: 44 84 5519 5091
Industries & Categories
Biotechnology, Health Diagnostics
Canonical: https://fsome.com/organization/activiomics-1853137 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.